Real-world use of seladelpar in adults with primary biliary cirrhosis
Collects everyday treatment data from adults with primary biliary cirrhosis taking seladelpar.
Plain-language title generated from the registry record
Registry title: Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- Clinic for Gastroenterology and Hepatology; University Hospital ZürichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Leipzig
- Trial code
- NCT07549607
- Record updated
- 24 April 2026
- Original description
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.Read full original descriptionShow less
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
Inclusion: Age ≥ 18 years; Diagnosis of PBC according to EASL criteria; Treatment with seladelpar; Written informed consent.
Exclusion: current or previous participation in a phase I to IV interventional clinical trial for seladelpar treatment of PBC; Pregnancy and breastfeeding.